Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Gastritis D005756 27 associated lipids
Gastrointestinal Diseases D005767 20 associated lipids
Glioma D005910 112 associated lipids
Glomerulonephritis D005921 35 associated lipids
Glomerulonephritis, IGA D005922 7 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Rhinitis, Allergic, Seasonal D006255 7 associated lipids
Heart Defects, Congenital D006330 20 associated lipids
Heart Failure D006333 36 associated lipids
Heart Septal Defects D006343 2 associated lipids
Heart Valve Diseases D006349 4 associated lipids
Hemolysis D006461 131 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Hemorrhagic Fever with Renal Syndrome D006480 3 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hydatidiform Mole D006828 3 associated lipids
Hyperaldosteronism D006929 4 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypercapnia D006935 5 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Hyperlipoproteinemia Type II D006938 22 associated lipids
Hyperemia D006940 25 associated lipids
Hyperlipidemias D006949 73 associated lipids
Hyperlipoproteinemias D006951 15 associated lipids
Hyperlipoproteinemia Type IV D006953 6 associated lipids
Hypersensitivity D006967 22 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Hypertension, Renal D006977 9 associated lipids
Hypertension, Renovascular D006978 10 associated lipids
Hypolipoproteinemias D007009 9 associated lipids
Hypotension D007022 41 associated lipids
Hypothyroidism D007037 32 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Infertility D007246 3 associated lipids
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Intermittent Claudication D007383 6 associated lipids
Jejunal Diseases D007579 3 associated lipids
Keratitis D007634 7 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Polycystic Kidney Diseases D007690 12 associated lipids
Leiomyosarcoma D007890 4 associated lipids
Leukemia, Lymphoid D007945 18 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Leukopenia D007970 9 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Oviedo PJ et al. Progestogens reduce thromboxane production by cultured human endothelial cells. 2011 Climacteric pmid:20443717
Li CH et al. [Effect of electroacupuncture at different acupoints on plasma TXB2 and 6-keto-PGF(1alpha), contents in dysmenorrhea rats]. 2011 Zhen Ci Yan Jiu pmid:22073886
Angiolillo DJ et al. Impact of a fixed-dose combination of naproxen and esomeprazole magnesium on serum thromboxane B2 inhibition by low-dose aspirin over 5 days in healthy adults: a phase I, randomized, double-blind, placebo-controlled, noninferiority trial. 2011 Clin Ther pmid:22078153
Sambu N et al. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study. 2011 Heart pmid:21795297
Spectre G et al. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. 2011 Thromb. Haemost. pmid:21800009
Hoh CM et al. Evaluation of effects of low-dose aspirin administration on urinary thromboxane metabolites in healthy dogs. 2011 Am. J. Vet. Res. pmid:21801060
Dalli E et al. Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers. 2011 Thromb. Res. pmid:21737127
Gao F et al. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease. 2011 Chin. Med. J. pmid:21740787
Puccetti L et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. 2011 Atherosclerosis pmid:21056418
Wójtowicz A et al. Aspirin resistance may be associated with adverse pregnancy outcomes. 2011 Neuro Endocrinol. Lett. pmid:21670728
Graziani F et al. Thromboxane production in morbidly obese subjects. 2011 Am. J. Cardiol. pmid:21439532
Cathcart MC et al. Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. 2011 Mol. Cancer pmid:21388528
Oh SH et al. Association analysis of thromboxane A synthase 1 gene polymorphisms with aspirin intolerance in asthmatic patients. 2011 Pharmacogenomics pmid:21449675
Akagi Y et al. Influence of nonsteroidal anti-inflammatory drugs on the antiplatelet effects of aspirin in rats. 2011 Biol. Pharm. Bull. pmid:21415533
Capodanno D et al. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. 2011 Circ Cardiovasc Interv pmid:21386092
Yan LG et al. Injectable caltrop fruit saponin protects against ischemia-reperfusion injury in rat brain. 2011 Am. J. Chin. Med. pmid:21476209
Liu JQ et al. Effects of tanshinone IIA, a major component of Salvia miltiorrhiza, on platelet aggregation in healthy newborn piglets. 2011 J Ethnopharmacol pmid:21453766
Halawani SH et al. Aspirin failure in patients presenting with acute cerebrovascular ischaemia. 2011 Thromb. Haemost. pmid:21544317
Bauer J et al. Arzanol, a prenylated heterodimeric phloroglucinyl pyrone, inhibits eicosanoid biosynthesis and exhibits anti-inflammatory efficacy in vivo. 2011 Biochem. Pharmacol. pmid:20933508
Kleinedler JJ et al. A dietary approach to increase in-stent stenosis and face validity of a rat model for arterial angioplasty and stenting. 2011 Atherosclerosis pmid:21982412
Moussa O et al. Urinary thromboxane B2 and thromboxane receptors in bladder cancer: opportunity for detection and monitoring. 2011 Prostaglandins Other Lipid Mediat. pmid:21983220
Chandrasekaran CV et al. Dual inhibitory effect of Glycyrrhiza glabra (GutGardâ„¢) on COX and LOX products. 2011 Phytomedicine pmid:20864324
Kleinbongard P et al. Acute vasomotor paralysis and potential downstream effects of paclitaxel from stents implanted for saphenous vein aorto-coronary bypass stenosis. 2011 Basic Res. Cardiol. pmid:21472462
Ceprnja M et al. Oxidative stress markers in patients with post-traumatic stress disorder. 2011 Coll Antropol pmid:22397253
Toliopoulos IK et al. Inhibition of platelet aggregation and immunomodulation of NK lymphocytes by administration of ascorbic acid. 2011 Indian J. Exp. Biol. pmid:22403863
Saihkay HN et al. Validating 123I-metaiodobenzylguanidine as a platelet marker for non-invasive imaging in rabbits. 2011 Jan-Feb J Pharmacol Toxicol Methods pmid:20646985
Brainard BM et al. Effects of clopidogrel and aspirin on platelet aggregation, thromboxane production, and serotonin secretion in horses. 2011 Jan-Feb J. Vet. Intern. Med. pmid:21143302
Alcott CJ et al. Clinical and immunomodulating effects of ketamine in horses with experimental endotoxemia. 2011 Jul-Aug J. Vet. Intern. Med. pmid:21745244
Chakroun T et al. The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients. 2011 Jul-Aug Genet Test Mol Biomarkers pmid:21434767
Thomason J et al. Platelet cyclooxygenase expression in normal dogs. 2011 Sep-Oct J. Vet. Intern. Med. pmid:21985141
Wen SH et al. Ischemic postconditioning during reperfusion attenuates intestinal injury and mucosal cell apoptosis by inhibiting JAK/STAT signaling activation. 2012 Shock pmid:22777122
Vazzana N et al. Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. 2012 J. Clin. Endocrinol. Metab. pmid:22761461
Zhou CB et al. Decrease in inflammatory response does not prevent placental dysfunction after fetal cardiac bypass in goats. 2012 J. Thorac. Cardiovasc. Surg. pmid:21821267
Ramadan E et al. Lamotrigine blocks NMDA receptor-initiated arachidonic acid signalling in rat brain: implications for its efficacy in bipolar disorder. 2012 Int. J. Neuropsychopharmacol. pmid:21733229
Cesari M et al. Oxidative damage, platelet activation, and inflammation to predict mobility disability and mortality in older persons: results from the health aging and body composition study. 2012 J. Gerontol. A Biol. Sci. Med. Sci. pmid:22389462
Barberà-Cremades M et al. P2X7 receptor-stimulation causes fever via PGE2 and IL-1β release. 2012 FASEB J. pmid:22490780
Su CL et al. Inducible cyclooxygenase expression mediating hypoxia/reoxygenation-induced pulmonary vasoconstriction is attenuated by a cyclooxygenase inhibitor in rats. 2012 Transplant. Proc. pmid:22564588
Ames PR et al. Aspirin insensitive thromboxane generation is associated with oxidative stress in type 2 diabetes mellitus. 2012 Thromb. Res. pmid:22521214
Andersson T et al. Evaluation of the pharmacodynamics of acetylsalicylic acid 81 mg with or without esomeprazole 20 mg in healthy volunteers. 2012 Am J Cardiovasc Drugs pmid:22631032
Skarke C et al. Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649. 2012 Clin. Pharmacol. Ther. pmid:22278334
Ledwidge MT et al. In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin? 2012 Atherosclerosis pmid:22326030
Chen C et al. [Effects of extracts of Radix Scrophulariae on blood pressure in spontaneously hypertensive rats and the underlying mechanisms]. 2012 Zhong Xi Yi Jie He Xue Bao pmid:22979933
Etulain J et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. 2012 Thromb. Haemost. pmid:22159527
Mayer AM et al. Marine sponge Hymeniacidon sp. amphilectane metabolites potently inhibit rat brain microglia thromboxane B2 generation. 2012 Bioorg. Med. Chem. pmid:22153874
Yang D et al. Effects of short- and long-term hypercholesterolemia on contrast-induced acute kidney injury. 2012 Am. J. Nephrol. pmid:22189165
Mustonen K et al. Dose-response investigation of oral ketoprofen in pigs challenged with Escherichia coli endotoxin. 2012 Vet. Rec. pmid:22735989
Zhao Y et al. [Effects of the effective components group of xiaoshuantongluo formula on rat acute blood stasis model]. 2012 Yao Xue Xue Bao pmid:22812003
Khandelwal AR et al. Resveratrol and quercetin interact to inhibit neointimal hyperplasia in mice with a carotid injury. 2012 J. Nutr. pmid:22718033
Guo S et al. Gastric mucosal damage in water immersion stress: mechanism and prevention with GHRP-6. 2012 World J. Gastroenterol. pmid:22791951
Matsuura E et al. On aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes. 2012 J. Thromb. Haemost. pmid:22784188